Literature DB >> 27960642

The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia.

P Carrasco Salas1, L Fernández2, M Vela3, D Bueno4, B González4, J Valentín3, P Lapunzina1, A Pérez-Martínez1,3,4.   

Abstract

The CDKN2A/B genes in the 9p21 chromosomal region are frequently involved in human cancer, including pediatric acute lymphoblastic leukemia (ALL). These genes encode 3 proteins that belong to the RB1 and TP53 pathways and act as tumor suppressors by regulating the G1/S checkpoint of the cell cycle. The prognostic value of deletions in the CDKN2A/B locus in ALL is controversial in part due to the limitations of the methodologies used. Further studies with advanced technologies are needed for elucidation. Future studies would also highlight whether CDK4/CDK6 selective inhibitors might be useful therapies for children with these genetic aberrations.

Entities:  

Keywords:  CDK4/CDK6 inhibitors; CDKN2A gene; CDKN2B gene; deletions; pediatric acute lymphoblastic leukemia; prognosis

Mesh:

Substances:

Year:  2016        PMID: 27960642     DOI: 10.1080/08880018.2016.1251518

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  9 in total

1.  Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis.

Authors:  Wanhua Zhang; Pu Kuang; Ting Liu
Journal:  Ann Med       Date:  2019-02-14       Impact factor: 4.709

Review 2.  Genetic Biomarkers and Their Clinical Implications in B-Cell Acute Lymphoblastic Leukemia in Children.

Authors:  Monika Lejman; Aleksandra Chałupnik; Zuzanna Chilimoniuk; Maciej Dobosz
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

3.  Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia.

Authors:  Karen L Bride; Hai Hu; Anastasia Tikhonova; Tori J Fuller; Tiffaney L Vincent; Rawan Shraim; Marilyn M Li; William L Carroll; Elizabeth A Raetz; Iannis Aifantis; David T Teachey
Journal:  Haematologica       Date:  2022-08-01       Impact factor: 11.047

Review 4.  Cyclin-dependent kinase inhibitors in malignant hematopoiesis.

Authors:  Alessia Schirripa; Veronika Sexl; Karoline Kollmann
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

5.  Gene Deletions and Prognostic Values in B-Linage Acute Lymphoblastic Leukemia.

Authors:  Qiuyun Fang; Yang Song; Xiaoyuan Gong; Jun Wang; Qinghua Li; Kaiqi Liu; Yahui Feng; Qishan Hao; Yan Li; Hui Wei; Guangji Zhang; Yuntao Liu; Benfa Gong; Ying Wang; Chunlin Zhou; Dong Lin; Bingcheng Liu; Shuning Wei; Runxia Gu; Yingchang Mi; Jianxiang Wang
Journal:  Front Oncol       Date:  2021-06-02       Impact factor: 6.244

Review 6.  New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update.

Authors:  Adrián Montaño; Maribel Forero-Castro; Darnel Marchena-Mendoza; Rocío Benito; Jesús María Hernández-Rivas
Journal:  Cancers (Basel)       Date:  2018-04-07       Impact factor: 6.639

7.  The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolution.

Authors:  Denise Anderson; Patrycja Skut; Anastasia M Hughes; Emanuela Ferrari; Jennifer Tickner; Jiake Xu; Benjamin H Mullin; Dave Tang; Sébastien Malinge; Ursula R Kees; Rishi S Kotecha; Timo Lassmann; Laurence C Cheung
Journal:  Sci Rep       Date:  2020-11-05       Impact factor: 4.379

Review 8.  Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.

Authors:  Hui Yu; Yuxin Du; Ji Xu; Mingzhi Zhang
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

9.  Clinical impacts of copy number variations in B-cell differentiation and cell cycle control genes in pediatric B-cell acute lymphoblastic leukemia: a single centre experience.

Authors:  Klementina Crepinsek; Gasper Marinsek; Marko Kavcic; Tomaž Prelog; Lidija Kitanovski; Janez Jazbec; Marusa Debeljak
Journal:  Radiol Oncol       Date:  2021-12-22       Impact factor: 2.991

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.